October 18, 2025Lara D. Veeken

Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study

View Full Paper

Ask AI

Bookmark

SGLT2 inhibitors led to a significant 37.6% reduction in proteinuria among lupus nephritis patients.
Decreased eGFR decline was noted, with annualized rates of -2.9 ml/min/1.73m2 post-SGLT2i initiation.
Increased haemoglobin and hematocrit levels were observed after SGLT2i treatment, evidencing broad health benefits.
Adverse events were low at 12%, with some requiring emergency medical attention, indicating the treatment's relative safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Before-and-after analysis shows SGLT2 inhibitors reduce proteinuria and improve eGFR in lupus nephritis, indicating potential benefits.

Ramírez-Mulhern et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark